

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Creso Pharma Limited

ABN

89 609 406 911

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

|   |   |  |
|---|---|--|
| 1 | +Class of +securities issued or to be issued  | <ol style="list-style-type: none"> <li>1. Unlisted Options</li> <li>2. Unlisted Options</li> </ol>   |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued   | <ol style="list-style-type: none"> <li>1. 24,377,710</li> <li>2. 200,000</li> </ol>  |
| 3 | Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | <ol style="list-style-type: none"> <li>1. Unlisted Options (exercisable at \$0.80 on or before 21 August 2020)</li> <li>2. Unlisted Options (exercisable at \$0.55 on or before 21 August 2021)</li> </ol> |

**Appendix 3B**  
**New issue announcement**

|   |   |
|---|---|
| <p>4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> | <ol style="list-style-type: none"> <li>1. No – Upon exercise and conversion into ordinary shares, the unlisted options will rank equally</li> <li>2. No - Upon exercise and conversion into ordinary shares, the unlisted options will rank equally</li> </ol>  |
| <p>5 Issue price or consideration</p>   | <ol style="list-style-type: none"> <li>1. Nil</li> <li>2. Nil</li> </ol>  |
| <p>6 Purpose of the issue<br/>         (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>  | <ol style="list-style-type: none"> <li>1. Entitlement Issue to reward the Company’s long-term Shareholders for their loyalty. The funds raised will be used primarily for the construction of the cannabis growing facility at the Mernova Medicinal Inc site in Nova Scotia, Canada, to fast track product development at Mernova, as well as the expenses of the Offer and working capital. <i>(Refer to Prospectus lodged with ASX on 25 July 2018).</i></li> <li>2. Issue of Unlisted Options to employee of the Company as part of remuneration package in accordance with employment contract.</li> </ol> |
| <p>6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i</p>   | <p>No</p>   |
| <p>6b The date the security holder resolution under rule 7.1A was passed</p>  | <p>N/A</p>  |

+ See chapter 19 for defined terms.

|    |   |  |                                  |
|----|---|--|----------------------------------|
| 6c | Number of +securities issued without security holder approval under rule 7.1  | 200,000 Unlisted Options ( <i>exercisable at \$0.55 on or before 21 August 2021</i> )    |                                  |
| 6d | Number of +securities issued with security holder approval under rule 7.1A  | N/A  |                                  |
| 6e | Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)   | N/A  |                                  |
| 6f | Number of +securities issued under an exception in rule 7.2   | 24,377,710 Unlisted Options ( <i>exercisable at \$0.80 on or before 21 August 2020</i> ) |                                  |
| 6g | If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.  | N/A  |                                  |
| 6h | If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements  | N/A  |                                  |
| 6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements  | 7.1 – 15,808,520<br>7.1A – N/A   |                                  |
| 7  | +Issue dates<br><br>Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.<br><br>Cross reference: item 33 of Appendix 3B. | 21 August 2018   |                                  |
| 8  | Number and +class of all +securities quoted on ASX ( <i>including</i> the +securities in section 2 if applicable)   | Number   | +Class                           |
|    |   | 92,525,543   | Ordinary fully paid shares (CPH) |

**Appendix 3B**  
**New issue announcement**

---

| Number | +Class |
|--------|--------|
|--------|--------|

---

+ See chapter 19 for defined terms.

|         |   |            |  |
|---------|---|------------|--|
| 9       | Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX (including the <sup>+</sup> securities in section 2 if applicable) | 8,000,001  | Ordinary fully paid shares subject to 24mths escrow (CPHESC1)  |
|         |   | 15,200,000 | Ordinary fully paid shares subject to escrow to 20 October 2018  |
|         |   | 250,000    | Unlisted Options (\$0.40; expiry 14/10/2018) subject to 24mths escrow (CPHOPT1)  |
|         |   | 600,000    | Unlisted Options (\$0.40; expiry 27/06/2020) subject to 12mths escrow (CPHOPT2)  |
|         |   | 2,886,250  | Unlisted Options (\$0.20; expiry 13/10/2020) subject to escrow to 13/10/2017) (CPHOPT3)  |
|         |   | 2,500,000  | Unlisted Options (\$0.20; expiry 13/10/2019) subject to 24mths escrow (CPHOPT4)  |
|         |   | 300,000    | Unlisted Options (\$0.50; expiry 23/01/2021) subject to vesting conditions   |
|         |   | 150,000    | Unlisted Options (\$0.80; expiry 13/07/2021) subject to vesting conditions   |
|         |   | 5,000,000  | Tranche 4 (Issue 1) Performance Rights (Subject to 24mths escrow) ( <i>Refer to Section 12.5 of Replacement Prospectus dated 08.08.16 for full terms</i> ) |
|         |   | 1,000,000  | Performance Shares (subject to escrow to 13/10/2017)   |
|         |   | 800,000    | Tranche 1 Performance Rights (subject to vesting conditions).  |
|         |   | 800,000    | Tranche 2 Performance Rights (subject to vesting conditions)   |
|         |   | 1,250,000  | Tranche 3 Performance Rights (subject to vesting conditions).  |
|         |   | 1,250,000  | Tranche 4 Performance Rights (subject to vesting conditions).  |
| 100,000 | Tranche 8 Performance Rights (subject to vesting conditions).   |            |  |
| 150,000 | Tranche 9 Performance Rights (subject to vesting conditions).   |            |  |

**Appendix 3B**  
**New issue announcement**

|   |  |   |
|---|--|---|
| Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX (including the <sup>+</sup> securities in section 2 if applicable) | 2,000,000  | Tranche 12 Performance Rights (subject to vesting conditions).                                    |
|   | 100,000  | Tranche 16 Performance Rights (subject to vesting conditions).                                    |
|   | 100,000  | Tranche 17 Performance Rights (subject to vesting conditions).                                    |
|   | 746,000  | Employee Performance Rights (subject to vesting conditions). Issue under Performance Rights Plan) |
|   | 100,000  | Unlisted Options (\$0.60; expiry 27/07/2020).   |
|   | 140,000  | Unlisted Options (\$0.40; expiry 27/07/2021). Subject to vesting conditions.                      |
|   | 250,000  | Unlisted Options (\$0.30; expiry 27/07/2019). Subject to vesting conditions.                      |
|   | 250,000  | Unlisted Options (\$0.80; expiry 13/04/2019)  |
|   | 24,377,710   | Unlisted Options (\$0.80; expiry 21/08/2020)  |
|   | 200,000  | Unlisted Options (\$0.535; expiry 27 July 2021)   |
|   | 200,000  | Unlisted Options (\$0.80; expiry 27 July 2022)  |
| 200,000   | Unlisted Options (\$0.55; expiry 21 August 2021)   |   |
| 10  | Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) | N/A   |

**Part 2 - Pro rata issue**

|    |  |   |
|----|--|---|
| 11 | Is security holder approval required?                                    | No  |
| 12 | Is the issue renounceable or non-renounceable?                           | Non-renounceable  |
| 13 | Ratio in which the <sup>+</sup> securities will be offered               | 1 option for every 2 shares held on the record date               |
| 14 | <sup>+</sup> Class of <sup>+</sup> securities to which the offer relates | Offer of options to eligible holders of shares at the record date |

+ See chapter 19 for defined terms.

|    |  |  |
|----|--|--|
| 15 | +Record date to determine entitlements   | 31 July 2018   |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?   | No   |
| 17 | Policy for deciding entitlements in relation to fractions  | Rounding Up  |
| 18 | Names of countries in which the entity has security holders who will not be sent new offer documents<br><br>Note: Security holders must be told how their entitlements are to be dealt with.<br>Cross reference: rule 7.7. | All countries except Australia, New Zealand, Israel, Switzerland and Singapore |
| 19 | Closing date for receipt of acceptances or renunciations   | 14 August 2018   |
| 20 | Names of any underwriters  | N/A  |
| 21 | Amount of any underwriting fee or commission   | N/A  |
| 22 | Names of any brokers to the issue  | N/A  |
| 23 | Fee or commission payable to the broker to the issue   | N/A  |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders   | N/A  |
| 25 | If the issue is contingent on security holders' approval, the date of the meeting  | N/A  |
| 26 | Date entitlement and acceptance form and offer documents will be sent to persons entitled  | 3 August 2018  |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders  | N/A  |
| 28 | Date rights trading will begin (if applicable)   | N/A  |

## Appendix 3B New issue announcement

---

|    |   |              |
|----|---|--------------|
| 29 | Date rights trading will end (if applicable)  | N/A          |
| 30 | How do security holders sell their entitlements <i>in full</i> through a broker?                            | N/A          |
| 31 | How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | N/A          |
| 32 | How do security holders dispose of their entitlements (except by sale through a broker)?                    | N/A          |
| 33 | +Issue date   | 25 July 2018 |

### Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

- 34 Type of +securities  
(tick one)
- (a)  +Securities described in Part 1
- (b)  All other +securities  
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

- 35  If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
- 36  If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
- 1 - 1,000
  - 1,001 - 5,000
  - 5,001 - 10,000
  - 10,001 - 100,000
  - 100,001 and over

---

+ See chapter 19 for defined terms.



37

A copy of any trust deed for the additional +securities

**Appendix 3B**  
**New issue announcement**

---

**Entities that have ticked box 34(b)**

|    |   |        |        |
|----|---|--------|--------|
| 38 | Number of +securities for which +quotation is sought  | N/A    |        |
| 39 | +Class of +securities for which quotation is sought   | N/A    |        |
| 40 | <p>Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> | N/A    |        |
| 41 | <p>Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another +security, clearly identify that other +security)</p>  | N/A    |        |
| 42 | Number and +class of all +securities quoted on ASX (including the +securities in clause 38)   | Number | +Class |
|    |   | N/A    |        |

---

+ See chapter 19 for defined terms.

## Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Sarah Smith  
(Company Secretary)

Date: 21 August 2018

== == == == ==

## Appendix 3B – Annexure 1

### Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

| <b>Rule 7.1 – Issues exceeding 15% of capital</b>  |   |
|--|---|
| <b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>  |   |
| <b>Insert</b> number of fully paid <sup>†</sup> ordinary securities on issue 12 months before the <sup>†</sup> issue date or date of agreement to issue  | <b>74,374,161</b>   |
| <b>Add</b> the following: <ul style="list-style-type: none"> <li>• Number of fully paid <sup>†</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>• Number of fully paid <sup>†</sup>ordinary securities issued in that 12 month period with shareholder approval</li> <li>• Number of partly paid <sup>†</sup>ordinary securities that became fully paid in that 12 month period</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>• Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>• It may be useful to set out issues of securities on different dates as separate line items</li> </ul> | <p>8,158,750 issued on 31 March 2017 and ratified on 27 July 2017<br/> 1,250,000 issued on 31 March 2017 and ratified on 27 July 2017<br/> 4,568,438 issued on 31 March 2017 ratified on 27 July 2017<br/> 2,094,154 ordinary shares issued on 27 July 2017 and ratified on 11 December 2017<br/> 1,000,000 ordinary shares issued 13 October 2017 and ratified on 11 December 2017<br/> 8,398,548 shares issued 1 December 2017 and ratified 31 May 2018<br/> 8,835,135 shares issued 1 December 2017 and ratified 31 May 2018<br/> 70,000 ordinary shares issued on the exercise of Options<br/> 3,500,000 ordinary shares issued on conversion of performance rights<br/> 2,000,000 ordinary shares issued on conversion of performance rights</p> |
| <b>Subtract</b> the number of fully paid <sup>†</sup> ordinary securities cancelled during that 12 month period  | Nil   |
| <b>“A”</b>   | <b>114,899,186</b>  |

|                                     |   |
|-------------------------------------|---|
| <b>Step 2: Calculate 15% of “A”</b> |   |
| <b>“B”</b>                          | 0.15<br><i>[Note: this value cannot be changed]</i> |
| <b>Multiply</b> “A” by 0.15         | 17,234,878  |

|  |  |
|--|--|
| <b>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</b> |  |
| <b>Insert</b> number of <sup>†</sup> equity securities issued or   |  |

<sup>†</sup> See chapter 19 for defined terms.

|   |   |
|---|---|
| <p>agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> | <p>250,000 ordinary shares issued 1 November 2017</p> <p>250,000 unlisted options issued 1 November 2017 – exercised on 27 November 2017.</p> <p>326,358 shares issued 21 December 2017 under Share Purchase Plan</p> <p>400,000 unlisted options issued 27 July 2018</p> <p>200,000 unlisted options issued 21 August 2018</p> |
| <b>“C”</b>  | <b>1,426,358</b>  |

**Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1**

|   |  |
|---|--|
| <p>“A” x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>          | 17,234,878   |
| <p><b>Subtract “C”</b></p> <p><i>Note: number must be same as shown in Step 3</i></p> | 1,426,358  |
| <p><b>Total</b> [“A” x 0.15] – “C”</p>  | 15,808,520 : this is the remaining placement capacity under rule 7.1 |

## Part 2

### Rule 7.1A – Additional placement capacity for eligible entities

**Step 1: Calculate “A”, the base figure from which the placement capacity is calculated**

|  |     |
|--|-----|
| <p><b>“A”</b></p> <p><i>Note: number must be same as shown in Step 1 of Part 1</i></p> | N/A |
|--|-----|

**Step 2: Calculate 10% of “A”**

|                                    |  |
|------------------------------------|--|
| <p><b>“D”</b></p>                  | <p>0.10</p> <p><i>Note: this value cannot be changed</i></p> |
| <p><b>Multiply “A” by 0.10</b></p> | N/A  |

**Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used**

|   |  |
|---|--|
| <p><b>Insert</b> number of <sup>+</sup>equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</p> <p><i>Notes:</i></p> <ul style="list-style-type: none"> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific</li> </ul> |  |
|---|--|

**Appendix 3B**  
**New issue announcement**

|  |  |
|--|--|
| <i>security holder approval has been obtained</i><br><ul style="list-style-type: none"> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul> |  |
| <b>“E”</b>   |  |

|  |  |
|--|--|
| <b>Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A</b> |  |
| <b>“A” x 0.10</b><br><i>Note: number must be same as shown in Step 2</i>                               | N/A  |
| <b>Subtract “E”</b><br><i>Note: number must be same as shown in Step 3</i>                             |  |
| <b>Total [“A” x 0.10] – “E”</b>  | N/A<br><i>Note: this is the remaining placement capacity under rule 7.1A</i> |

---

+ See chapter 19 for defined terms.